Indolent Non-hodgkin Lymphoma

• CLINICAL_TRIALS withdrawal · 2025-12-18
  Clinical Trial Update: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies [Phase 1]

  A Phase 1 study of CNTY-101 in CD19-positive B-cell malignancies has been terminated.

• CLINICAL_TRIALS withdrawal · 2025-09-17
  Clinical Trial Update: Testing the Safety of CB-5339 in Patients With Cancer [Phase 1]

  The Phase 1 clinical trial of CB-5339 in cancer patients has been withdrawn, with no study results reported.

• CLINICAL_TRIALS withdrawal · 2021-03-17
  Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]

  Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.

• CLINICAL_TRIALS withdrawal · 2020-10-19
  Clinical Trial Update: Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma [Phase 3]

  A Phase 3 trial evaluating fludarabine and rituximab with or without pixantrone for relapsed/refractory indolent non-Hodgkin lymphoma has be…

• CLINICAL_TRIALS withdrawal · 2018-04-19
  Clinical Trial Update: Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

  A clinical trial evaluating interferon-free antiviral therapy for patients with Hepatitis C-positive genotype 1b–associated indolent non-Hod…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2016-02-15
  Clinical Trial Update: Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL [Phase 2]

  A Phase 2 trial evaluating a single dose of 90Y-ibritumomab tiuxetan in patients with low tumor burden, untreated or indolent non-Hodgkin ly…

• CLINICAL_TRIALS withdrawal · 2015-10-12
  Clinical Trial Update: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas [Phase 2]

  This clinical trial update notes that the Phase 2 study of the anti-CD20 antibody ofatumumab in older patients with untreated indolent B-cel…

• CLINICAL_TRIALS withdrawal · 2015-01-19
  Clinical Trial Update: Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma [Phase 3]

  A Phase 3 trial evaluating pixantrone in combination with rituximab for indolent non-Hodgkin lymphoma was terminated.